NY-ESO-1 targeted self-adjuvanting peptide vaccines (SapVax)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameNY-ESO-1 targeted self-adjuvanting peptide vaccines (SapVax)
Drug Alias NameNY-ESO-1 targeting synthetic peptide (University of Auckland)SV-283
ClassificationBiologics > Protein drugs > Recombinant polypeptideVaccines > Application > Therapeutic vaccine
Mechanisms of ActionCancer/testis antigen 1 modulatorsToll like receptor 2 agonists
TargetsToll like receptor 2Cancer/testis antigen 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew Zealand
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe University Of Auckland
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAuckland Uniservices LtdSapVax LLCThe University Of Auckland
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A